Trojan

Trojan Horse Therapeutics (THT) is a biotechnology company focused on developing a proprietary platform for the targeted delivery of therapeutic payloads directly to diseased cells. By utilizing a 'Trojan Horse' approach, the company aims to enhance the efficacy and reduce the toxicity of potent drugs, particularly in the field of oncology. Their technology involves encapsulating or conjugating therapeutic agents within delivery vehicles that are specifically recognized and internalized by target cells. This strategy is designed to overcome biological barriers and improve the therapeutic index of various modalities, including small molecules and biologics. THT is currently in the pre-clinical stage, advancing its lead programs toward IND-enabling studies.